Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Aridis Pharmaceuticals Inc's Business Segments
Aridis Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Aridis Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Grant100%
- License0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 0 | 100% |
| License | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development of novel immunotherapies to combat infectious diseases. The company is headquartered in San Jose, California, and was founded in 2003. Aridis Pharmaceuticals aims to address the rapidly growing global health problem of antibiotic-resistant infections with its innovative approach.
The company's primary focus is on developing monoclonal antibodies (mAbs) that specifically target and neutralize bacterial and viral pathogens. They use a proprietary technology platform called MabIgX to discover and develop these mAbs. This platform combines high-throughput robotics, live pathogen screening, and bioinformatics to identify and select potential therapeutic candidates. By targeting specific sites on pathogens, Aridis Pharmaceuticals aims to not only prevent infection but also improve the body's natural immune defenses.
One of the key advantages of Aridis Pharmaceuticals' approach is the potential to provide more effective treatments against multi-drug-resistant pathogens. Antibiotic resistance has become a global health crisis, making traditional antibiotics less effective. Aridis Pharmaceuticals believes that its mAbs can overcome this challenge, offering a novel therapeutic modality that can tackle evolving and resilient pathogens.
While initially focusing on infectious diseases, Aridis Pharmaceuticals has expanded its pipeline to include mAbs for other indications, such as pulmonary disorders and inflammation-related diseases. The company's technology platform allows for the identification and development of antibodies against various targets, presenting a broad range of potential therapeutic opportunities.
Aridis Pharmaceuticals has also established collaborations and partnerships with leading academic institutions, government agencies, and pharmaceutical companies to accelerate the development and commercialization of its products. These partnerships help provide additional resources, expertise, and access to large patient populations for clinical trials.
From a manufacturing perspective, Aridis Pharmaceuticals has developed a scalable and efficient process for producing its monoclonal antibodies. The company aims to streamline production and achieve cost-effectiveness to ensure broader accessibility of its therapies.
In terms of clinical development, Aridis Pharmaceuticals has several programs in various stages. This includes treatments for ventilator-associated pneumonia, hospital-acquired pneumonia, and lung infections caused by Pseudomonas aeruginosa, among others. The company has successfully completed numerous preclinical and clinical studies, demonstrating the safety and efficacy of its mAb candidates.
Overall, Aridis Pharmaceuticals is a biopharmaceutical company at the forefront of developing innovative treatments for infectious diseases and other indications. With its proprietary technology platform and focus on mAbs, the company holds great potential to address the urgent medical needs of patients worldwide.
The company's primary focus is on developing monoclonal antibodies (mAbs) that specifically target and neutralize bacterial and viral pathogens. They use a proprietary technology platform called MabIgX to discover and develop these mAbs. This platform combines high-throughput robotics, live pathogen screening, and bioinformatics to identify and select potential therapeutic candidates. By targeting specific sites on pathogens, Aridis Pharmaceuticals aims to not only prevent infection but also improve the body's natural immune defenses.
One of the key advantages of Aridis Pharmaceuticals' approach is the potential to provide more effective treatments against multi-drug-resistant pathogens. Antibiotic resistance has become a global health crisis, making traditional antibiotics less effective. Aridis Pharmaceuticals believes that its mAbs can overcome this challenge, offering a novel therapeutic modality that can tackle evolving and resilient pathogens.
While initially focusing on infectious diseases, Aridis Pharmaceuticals has expanded its pipeline to include mAbs for other indications, such as pulmonary disorders and inflammation-related diseases. The company's technology platform allows for the identification and development of antibodies against various targets, presenting a broad range of potential therapeutic opportunities.
Aridis Pharmaceuticals has also established collaborations and partnerships with leading academic institutions, government agencies, and pharmaceutical companies to accelerate the development and commercialization of its products. These partnerships help provide additional resources, expertise, and access to large patient populations for clinical trials.
From a manufacturing perspective, Aridis Pharmaceuticals has developed a scalable and efficient process for producing its monoclonal antibodies. The company aims to streamline production and achieve cost-effectiveness to ensure broader accessibility of its therapies.
In terms of clinical development, Aridis Pharmaceuticals has several programs in various stages. This includes treatments for ventilator-associated pneumonia, hospital-acquired pneumonia, and lung infections caused by Pseudomonas aeruginosa, among others. The company has successfully completed numerous preclinical and clinical studies, demonstrating the safety and efficacy of its mAb candidates.
Overall, Aridis Pharmaceuticals is a biopharmaceutical company at the forefront of developing innovative treatments for infectious diseases and other indications. With its proprietary technology platform and focus on mAbs, the company holds great potential to address the urgent medical needs of patients worldwide.
Aridis Pharmaceuticals Inc. is a biotechnology company that specializes in the discovery and development of therapeutic monoclonal antibodies and other biologics. The company primarily focuses on addressing unmet medical needs caused by serious infections, with an emphasis on respiratory and infectious diseases.
Segments
1. Infectious Disease Therapeutics: Aridis Pharmaceuticals concentrates on the development of advanced antibacterial and antiviral therapies designed to combat multidrug-resistant pathogens. This segment aims to deliver solutions for patients suffering from serious infections that are difficult to treat, particularly in the hospital setting.
2. Respiratory Disease Solutions: This segment targets conditions associated with respiratory infections, where the development of antibodies can provide immediate and effective treatment options for patients, especially those with compromised immune responses.
3. Immunotherapy: With a commitment to innovating immunological approaches, Aridis is engaged in creating therapies that harness the body’s immune system to fight off infections and diseases more effectively. This includes products aimed at enhancing immune system responses to various pathogens.
Products
1. Monoclonal Antibodies: Aridis focuses heavily on monoclonal antibody technologies, developing candidates that can neutralize specific pathogens. These products are designed for various serious infections, especially those that exhibit antibiotic resistance.
- AR-301 (also known as A. baumannii antibody): Targeting Acinetobacter baumannii, a notorious antibiotic-resistant pathogen responsible for serious infections in healthcare settings. AR-301 is designed to prevent and treat infections caused by this bacterium.
- AR-501 (currently in clinical development): This product is designed to target Pseudomonas aeruginosa, another challenging pathogen often linked with respiratory infections in immunocompromised patients. It aims to improve patient outcomes in cases where traditional antibiotics are ineffective.
2. Antiviral Therapies: Aridis is exploring human monoclonal antibodies to treat viral infections, providing innovative solutions to combat prevalent viruses that can lead to significant morbidity and mortality.
3. Therapeutic Platforms: The company uses its proprietary platform technologies to develop its products more efficiently. This includes methods like rapid antibody discovery, optimization processes, and unique delivery mechanisms.
Services
1. Collaborations and Partnerships: Aridis engages in strategic partnerships with other pharmaceutical and biotechnology companies to augment its research capabilities. They work with academic institutions and international research organizations to accelerate the development of their therapeutic candidates.
2. Clinical Development Services: The company offers expertise in the varied phases of clinical development, from early-phase trials to more advanced study designs aimed at regulatory approval. This involves not just product development, but also patient recruitment, clinical trial management, and regulatory submissions.
3. Consulting and Research Support: Aridis provides consulting services for firms seeking expertise in infectious disease therapeutics and monoclonal antibody development. This includes support in preclinical research, validation of antibody candidates, and translational medicine strategies.
4. Manufacturing and Quality Control Services: Ensuring the quality and efficacy of their therapeutic products, Aridis emphasizes high standards in manufacturing processes. They may provide quality assurance services to maintain compliance with regulatory standards for production.
5. Market Access and Commercialization Strategies: As part of their organizational capabilities, Aridis develops strategies to facilitate market access for their products including health economics, reimbursement strategies, and commercialization planning.
In summary, Aridis Pharmaceuticals Inc. focuses on creating a range of innovative biologic products primarily aimed at treating serious infections and supporting respiratory health. The company leverages advanced monoclonal antibody technology and collaborates with other organizations to enhance its product offerings and clinical development.
Segments
1. Infectious Disease Therapeutics: Aridis Pharmaceuticals concentrates on the development of advanced antibacterial and antiviral therapies designed to combat multidrug-resistant pathogens. This segment aims to deliver solutions for patients suffering from serious infections that are difficult to treat, particularly in the hospital setting.
2. Respiratory Disease Solutions: This segment targets conditions associated with respiratory infections, where the development of antibodies can provide immediate and effective treatment options for patients, especially those with compromised immune responses.
3. Immunotherapy: With a commitment to innovating immunological approaches, Aridis is engaged in creating therapies that harness the body’s immune system to fight off infections and diseases more effectively. This includes products aimed at enhancing immune system responses to various pathogens.
Products
1. Monoclonal Antibodies: Aridis focuses heavily on monoclonal antibody technologies, developing candidates that can neutralize specific pathogens. These products are designed for various serious infections, especially those that exhibit antibiotic resistance.
- AR-301 (also known as A. baumannii antibody): Targeting Acinetobacter baumannii, a notorious antibiotic-resistant pathogen responsible for serious infections in healthcare settings. AR-301 is designed to prevent and treat infections caused by this bacterium.
- AR-501 (currently in clinical development): This product is designed to target Pseudomonas aeruginosa, another challenging pathogen often linked with respiratory infections in immunocompromised patients. It aims to improve patient outcomes in cases where traditional antibiotics are ineffective.
2. Antiviral Therapies: Aridis is exploring human monoclonal antibodies to treat viral infections, providing innovative solutions to combat prevalent viruses that can lead to significant morbidity and mortality.
3. Therapeutic Platforms: The company uses its proprietary platform technologies to develop its products more efficiently. This includes methods like rapid antibody discovery, optimization processes, and unique delivery mechanisms.
Services
1. Collaborations and Partnerships: Aridis engages in strategic partnerships with other pharmaceutical and biotechnology companies to augment its research capabilities. They work with academic institutions and international research organizations to accelerate the development of their therapeutic candidates.
2. Clinical Development Services: The company offers expertise in the varied phases of clinical development, from early-phase trials to more advanced study designs aimed at regulatory approval. This involves not just product development, but also patient recruitment, clinical trial management, and regulatory submissions.
3. Consulting and Research Support: Aridis provides consulting services for firms seeking expertise in infectious disease therapeutics and monoclonal antibody development. This includes support in preclinical research, validation of antibody candidates, and translational medicine strategies.
4. Manufacturing and Quality Control Services: Ensuring the quality and efficacy of their therapeutic products, Aridis emphasizes high standards in manufacturing processes. They may provide quality assurance services to maintain compliance with regulatory standards for production.
5. Market Access and Commercialization Strategies: As part of their organizational capabilities, Aridis develops strategies to facilitate market access for their products including health economics, reimbursement strategies, and commercialization planning.
In summary, Aridis Pharmaceuticals Inc. focuses on creating a range of innovative biologic products primarily aimed at treating serious infections and supporting respiratory health. The company leverages advanced monoclonal antibody technology and collaborates with other organizations to enhance its product offerings and clinical development.